Shattuck Labs Inc (STTK) is not a strong buy for a beginner investor with a long-term focus at this time. While there are positive catalysts in the form of upcoming Phase 1 data and bullish analyst ratings, the company's financial performance is weak, and there are no strong trading signals or recent influential trades to support immediate action. The stock's technical indicators suggest a neutral to slightly bullish trend, but the lack of significant trading trends and weak financials make it a hold rather than a buy.
The technical indicators show a slightly bullish trend with MACD above 0 and positively contracting, RSI at 72.498 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level R1 (6.633), with a pre-market price of 6.49. However, the stock trend analysis indicates a 50% chance of a negative return over the next day, week, and month.

Upcoming Phase 1 data for SL-325 in Q2 2026 is expected to highlight differentiation versus competitors, and analysts see high potential for success. The pre-market price is up 2.85%, indicating some positive sentiment.
Weak financial performance in Q4 2025, with net income down -32.58% YoY and EPS down -67.57% YoY. No significant hedge fund or insider trading trends, and no recent news or congress trading data to act as a catalyst. Stock trend analysis suggests a potential decline in the short term.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$12.59M (down -32.58% YoY), and a significant drop in EPS (-67.57% YoY). Gross margin remained at 100%, but overall financials are weak and do not support a strong buy case.
Analysts are generally bullish, with multiple firms raising price targets significantly. Needham has a $14 target with a Buy rating, and Piper Sandler has a $15 target with an Overweight rating. Citi and Wedbush have also raised targets, with upside catalysts expected in Q2 2026. However, Citi maintains a Neutral rating, indicating some caution.